title: Accelerated suppression of primary Epstein-Barr virus infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy.
abstract: We compared primary Epstein-Barr virus (EBV) infection and suppression between Kenyan human immunodeficiency virus-infected infants starting nevirapine-based vs lopinavir/ritonavir-based antiretroviral regimens. Although the rate of EBV infection was similar between groups, infants receiving lopinavir/ritonavir suppressed EBV more rapidly. Our findings suggest that specific antiretrovirals may potentially impact the risk of future EBV-associated malignancies.
authors.affiliation: Department of Global Health.
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Slyker
authors.forename: Corey
authors.initials: C
authors.lastname: Casper
authors.forename: Kenneth
authors.initials: K
authors.lastname: Tapia
authors.forename: Barbra
authors.initials: B
authors.lastname: Richardson
authors.forename: Lisa
authors.initials: L
authors.lastname: Bunts
authors.forename: Meei-Li
authors.initials: ML
authors.lastname: Huang
authors.forename: Dalton
authors.initials: D
authors.lastname: Wamalwa
authors.forename: Sarah
authors.initials: S
authors.lastname: Benki-Nugent
authors.forename: Grace
authors.initials: G
authors.lastname: John-Stewart
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D020031:Epstein-Barr Virus Infections / Q000517:prevention & control*; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007630:Kenya; D061466:Lopinavir; D019829:Nevirapine / Q000627:therapeutic use*; D012307:Risk Factors; D019438:Ritonavir / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D061466:Lopinavir; D019829:Nevirapine; D019438:Ritonavir
keywords: Epstein-Barr virus; HIV; antiretroviral therapy; infant; primary infection